Apiam Animal Health (ASX:AHX) - Managing Director, Dr Chris Richards
Managing Director, Dr Chris Richards
Source: Finance News Network
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Apiam Animal Health (AHX) has successfully completed an institutional placement and raised $6 million
  • All up, 7.5 million fully-paid ordinary shares were issued to institutional investors at 80 cents
  • This price equated to a 5.9 per cent discount to Apiam’s last trading price of 85 cents on April 14
  • Apiam will use the funds to speed up its regional expansion and assess new acquisition opportunities
  • Shares in Apiam are down a slight 1.18 per cent and are trading at 84 cents

Apiam Animal Health (AHX) has successfully completed an institutional placement and raised $6 million.

All up, 7.5 million fully-paid ordinary shares were issued to institutional investors at 80 cents.

This price represents a 5.9 per cent discount to Apiam’s last trading price of 85 cents on April 14, and a 5.6 per cent discount to the 10-day volume-weighted average price.

Apiam will use the funds to speed up its regional expansion and assess new acquisition opportunities.

Recently, there has been a rapid acceleration in pet ownership in regional areas, creating a favourable veterinary market.

Due to this, Apiam has opened two new purpose-built clinics in Shepparton and Torquay North in Victoria.

“The rapid growth in pet and production animal ownership in regional corridors, particularly as a result of changing population demographics and favourable seasonal corridors, has presented a very exciting market opportunity for Apiam,” Managing Director Dr Chris Richards commented.

“This placement will support us in accelerating our regional expansion plans and capturing the significant growth we are seeing in many veterinary areas,” he said.

“As an established regional player, Apiam is well placed to scale-up and leverage these opportunities as they emerge,” he added.

Shares in Apiam are down a slight 1.18 per cent and are trading at 84 cents at 3:56 pm AEST.

AHX by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…